Windlas Biotech Limited has announced a scheduled virtual meeting with analysts and institutional investors, set to take place on April 20, 2026. The pharmaceutical company formally notified both BSE Limited and National Stock Exchange of India Limited about this investor engagement on April 15, 2026.

Meeting Details and Schedule

The company has organized a group investor meeting with the following specifications:

Regulatory Compliance and Information Sharing

The notification was issued pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Windlas Biotech has explicitly stated that the company will reference only publicly available documents during discussions with investors and analysts.

The company has provided clear assurance that no unpublished price sensitive information (UPSI) will be shared during the meeting, maintaining compliance with regulatory requirements for investor interactions.

Administrative Details

Company Secretary and Compliance Officer Ananta Narayan Panda signed the official notification, acknowledging that potential schedule changes may occur due to exigencies on the part of investors, analysts, or the company itself. The notification was formally submitted to both major Indian stock exchanges on April 15, 2026.

This investor meeting represents part of Windlas Biotech's ongoing engagement with the investment community, providing a platform for discussions about the company's operations and performance based on publicly disclosed information.

Windlas Biotech Limited has announced a Board of Directors meeting scheduled for April 17, 2026, to consider a significant corporate action involving the buyback of its equity shares. The pharmaceutical company has informed stock exchanges about this development through a formal communication dated April 14, 2026.

Board Meeting Details

The upcoming board meeting will focus on a comprehensive review and approval of the share buyback proposal. The company has outlined the key aspects of this corporate action in its regulatory filing.

Regulatory Compliance Framework

The proposed buyback will be conducted in strict adherence to multiple regulatory requirements. The company has emphasized compliance with the Companies Act, 2013, including rules framed thereunder, and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018, as amended. All matters necessary and incidental to the buyback process will be addressed during the board deliberations.

Trading Window Restrictions

Windlas Biotech has implemented trading restrictions for designated persons as part of its insider trading prevention measures. The company has provided specific details regarding the current trading window closure.

These restrictions are implemented pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Regulating, Monitoring & Reporting of Trading.

Corporate Communication

The announcement was made through official communications to both major stock exchanges where the company's shares are listed. Windlas Biotech has requested the exchanges to take this information on record, ensuring transparency and regulatory compliance in its corporate actions.